CDKN2B Antibody

Code CSB-PA927883
Size US$297Purchase it in Cusabio online store
(only available for customers from the US)
Image
  • Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using p15 INK antibody.
  • Immunofluorescence analysis of HeLa cells, using p15 INK antibody.
  • Western blot analysis of extracts from HeLa cells, using p15 INK antibody.
  • Western blot analysis of extracts from 293 cells (Lane 2), using p15 INK antiobdy. The lane on the left is treated with synthesized peptide.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) CDKN2B Polyclonal antibody
Uniprot No. P42772
Target Names CDKN2B
Alternative Names CDK inhibitory protein antibody; CDK4B Inhibitor antibody; Cdkn2b antibody; CDN2B_HUMAN antibody; Cyclin dependent kinase 4 inhibitor B antibody; Cyclin Dependent Kinase Inhibitor 2B antibody; Cyclin dependent kinase inhibitor 2B p15 inhibits CDK4 antibody; Cyclin dependent kinases 4 and 6 binding protein antibody; Cyclin-dependent kinase 4 inhibitor B antibody; INK4B antibody; MTS 2 antibody; MTS-2 antibody; MTS2 antibody; Multiple tumor suppressor 2 antibody; Multiple Tumor Supressor 2 antibody; OTTHUMP00000021154 antibody; OTTHUMP00000021155 antibody; p14 CDK inhibitor antibody; p14 INK4b antibody; p14-INK4b antibody; P15 antibody; p15 CDK inhibitor antibody; p15 inhibits CDK4 antibody; p15 INK4b antibody; p15-INK4b antibody; p15INK4B antibody; TP 15 antibody; TP15 antibody
Raised in Rabbit
Species Reactivity Human,Mouse,Rat
Immunogen Synthesized peptide derived from Human p15 INK antibody.
Immunogen Species Homo sapiens (Human)
Clonality Polyclonal
Purification Method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration It differs from different batches. Please contact us to confirm it.
Form Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications ELISA,WB,IHC,IF
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:3000
IHC 1:50-1:100
IF 1:100-1:500
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.
Gene References into Functions
  1. Concurrent mutations, in genes such as CDKN2B or RB1, were associated with worse clinical outcome in lung adenocarcinoma patients with EGFR active mutations. PMID: 29343775
  2. CDKN2B expression in HPDE6-C7 human pancreatic ductal cells is induced by oncogenic KRAS via TGF-beta signaling. PMID: 28892048
  3. findings suggest that the GG genotype of the CDKN2B-AS1 gene variant rs4977574, which has been previously associated with an increased CAD risk, is also associated with a decreased susceptibility to the development of hypertension PMID: 29791233
  4. CDKN2B gene locus is a cardiovascular risk in ethnic Saudi Arabs PMID: 29894795
  5. ANRIL plays an important role in the formation of atherosclerosis, and the artificial modification of ANRIL transcripts should be considered following the development of this disease. (Review) PMID: 29270737
  6. CDKN2A/B locus SNPs may impact T2D risk by modulating islet gene expression and beta-cell proliferation. PMID: 29432124
  7. Complete methylation and loss of p15 gene expression causes susceptibility to relapse and decreased survival in APL patients. Thus, p15 promoter hypermethylation is a prospective prognostic indicator and a reliable clinical aid in assessment of patients with APL. PMID: 28052659
  8. Patients with higher levels of DNA methylation of CDKN2B may bear increased risk for aortic arch calcification PMID: 27773886
  9. E2F1 induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1/CDKN2B signaling axis. PMID: 28569791
  10. ANRIL may reduce p15INK4B expression through inhibiting TGF-beta/Smad signaling pathway, promoting invasion and metastasis of TC cells, and the silencing of ANRIL inhibits the invasion and metastasis of TPC-1 cells PMID: 27507052
  11. The obtained data suggested a negative association between copy number variation of the CDK2B genes and Atherothrombotic stroke. PMID: 28477716
  12. Among 8 SNPs in 3 loci that showed at least nominal association (P < 5.00E-02) in the primary cohort, a representative SNP for each loci (rs2157719 for CDKN2B-AS1, rs33912345 for SIX6, and rs9913911 for GAS7) were selected PMID: 29261660
  13. Results show that expression of CDKN2B was reduced significantly in colorectal cancer (CRC) and its promotor is targeted by miR-18b which controls its regulation. PMID: 28784723
  14. Mechanistic investigations demonstrated that BLACAT1 had a key role in G1/G0 arrest, and showed that BLACAT1 can repress p15 expression by binding to EZH2, thus contributing to the regulation of CRC cell cycle and proliferation. Our results suggest that BLACAT1, as a cell cycle regulator, may serve as a potential target for colon cancer prevention and treatment in human CRC PMID: 28277544
  15. DNA methylation of CDKN2B may play a potential role in artery calcification. PMID: 27905995
  16. These data support the hypothesis that decreased p15 expression is a robust biomarker for distinguishing nevus from melanoma. PMID: 27855847
  17. Total 1208 differentially expressed genes were screened, and 5 coronary artery disease (CAD)-associated miRNAs (including miR-92a) were predicted associated with CAD. The SVM classifier was constructed based on the 41 featured genes and had high recognition efficiency. Only one lncRNA CDKN2B-antisense targeting miR-92a was obtained. PMID: 28760552
  18. Upregulation of ZEB1-AS1 colorectal cancer promotes cell proliferation and inhibits cell apoptosis. In addition, cell cycle inhibitory protein p15 participates in the oncogenic function of ZEB1-AS1. Collectively, ZEB1-AS1 has asignificant effect on colorectal cancer pathological process and serves as a valuable prognostic biomarker for colorectal cancer. PMID: 28618933
  19. Genetic association analyses using the cpRNFLT with 768 points suggest that the CDKN2B gene was associated with paracentral/lower hemifield scotomas. PMID: 28472212
  20. We found that CDKN2B was a virtual target of miR-15a-5p with potential binding sites in the 3'UTR of CDKN2B (77-83 bp). We also showed that miR-15a-5p could bind to the CDKN2B 3'UTR. The data revealed a negative regulatory role of miR-15a-5p in the apoptosis of smooth muscle cells via targeting CDKN2B, and showed that miR-15a-5p could be a novel therapeutic target of AAA. PMID: 28214350
  21. Meta-analysis indicates that CDKN2B gene rs1063192 polymorphism is significantly associated with a decreased risk of glaucoma. [meta-analysis] PMID: 28416752
  22. results suggest that the cyclin dependent kinase inhibitor 2B rs10811656 locus might be associated with coronary artery disease in a Chinese Han population PMID: 27507036
  23. Polymorphism rs1063192 in CDKN2B is not a risk factor for Open-Angle Glaucoma in Saudi cohort. PMID: 27541204
  24. The CC genotype of CDKN2B rs1063192 in the hsa-miR-323b-5p binding site increased the risk of gestational diabetes mellitus in pregnant Chinese Han women PMID: 25990668
  25. Genetic risk variants in the CDKN2B gene is associated with somatic biomarkers in glioma. PMID: 26839018
  26. Aberrant methylation of the promoter regions of the p15INK4b gene in patients with acute myeloid leukemias. PMID: 27459612
  27. Inhibited HO-1 expression attenuated the hypermethylation of CDKN2B by suppressing DNMT1, which was conducive to treatment by cooperating with decitabine. PMID: 26782424
  28. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals PMID: 26470845
  29. This study investigated the potential roles of CDKN2B-related piRNA in leukemia cells to provide a potential tumorigenesis model of leukemia PMID: 26205624
  30. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma PMID: 26183406
  31. Children with ALL have higher levels of p15 CpG island methylation than a control group of children with ITP. PMID: 26501552
  32. High expression of p15 antisense RNA is associated with acute myeloid leukemia. PMID: 27060304
  33. CDKN2B variants are associated with pediatric B-cell precursor acute lymphoblastic leukemia. PMID: 26868379
  34. Loss of CDKN2B may not only promote cardiovascular disease through the development of atherosclerosis but may also impair TGFbeta signaling and hypoxic neovessel maturation. PMID: 26596284
  35. CD93 regulates LSC self-renewal by silencing CDKN2B in MLL leukemia PMID: 26387756
  36. The treatment of Raji cell line with 10 muM curcumin caused hypomethylation of the p15 promoter after six days. This led to the up-regulation of p15 and down-regulation of DNA methyltransferase 1. PMID: 26333125
  37. Findings identify germline CDKN2B mutations as a novel cause of familial renal cell carcinoma. PMID: 25873077
  38. There was no association between germline coding CDKN2B variants and B cell acute lymphoblastic leukemia in children. PMID: 26104880
  39. Results show that ANRIL positively regulates the proliferation of cancer cells, via regulating p15 and other genes related to G2/M phase control. PMID: 26408699
  40. these data show that DC-SCRIPT acts as a novel regulator of CDKN2B and induces cell cycle arrest in ESR1-positive breast cancer cells. PMID: 25663546
  41. silencing of p15 gene expression by epigenetic modification such as promoter hypermethylation plays a role not only in the initiation of multiple myeloma but also in plasma cell malignant transformation, disease progression, and development PMID: 25382971
  42. promoter methylation of p15 gene could have prognostic value in diffuse large B-cell lymphoma patients. PMID: 24815848
  43. CDKN2B locus deletion is associated with melanoma brain metastases. PMID: 24968695
  44. genotypes of the polymorphic markers of KCNJ11, SLC30A8 and CDKN2B genes showed the presence of association with T2DM in Russian population, while for the FTO gene was not found statistically significant associations with type 2 diabetes PMID: 25916116
  45. CDKN2B polymorphism is associated with the development of coronary atherosclerosis. PMID: 24573017
  46. Single nucleotide polymorphisms in CDKN2B gene are associated with cancer. PMID: 25239644
  47. Exogenous p15 protein expression combined with STI571 appeared to have a synergistic effect on proliferation inhibition and apoptosis induction in K562 cells. PMID: 24938701
  48. Investigate the relationship between urinary nickel and methylation of p16 in workers exposed to nickel. The levels of urinary nickel were significantly associated with the methylation of p15. PMID: 24806561
  49. CDKN2B upregulation was found in myelodysplastic syndrome mesenchymal stem cells. PMID: 24943834
  50. Loss of p15INK4b was associated with older age. PMID: 24716938

Show More

Hide All

Subcellular Location Cytoplasm
Protein Families CDKN2 cyclin-dependent kinase inhibitor family
Tissue Specificity Isoform 2 is expressed in normal (keratinocytes, fibroblasts) and tumor cell lines.
Database Links

HGNC: 1788

OMIM: 600431

KEGG: hsa:1030

STRING: 9606.ENSP00000276925

UniGene: Hs.72901

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1